# Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

> **NCT00803049** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 742 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Teriflunomide (HMR1726)

## Key facts

- **NCT ID:** NCT00803049
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 742 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00803049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00803049, "Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00803049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*